Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Squamous Intraepithelial Lesions 4Uterine Cervical Neoplasms 3Uterine Cervical Dysplasia 2Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1Papillomavirus Infections 1Head and Neck Squamous Cell Cancer 1HIV Seropositivity 1Anus Neoplasms 1

Interventions

Fluorouracil 12Radiotherapy 8Cisplatin 8pembrolizumab 4Papillomavirus Vaccines 4Mitomycin 4Irinotecan 4Cyclophosphamide 4Cetuximab 4Light Coagulation 3Interleukin-12 Subunit p35 3Capecitabine 3fludarabine phosphate 2fludarabine 2atezolizumab 2aldesleukin 2Watchful Waiting 2Vaccines 2Trastuzumab 2Surveys and Questionnaires 2Radiation 2Quality of Life 2Paclitaxel 2Oxaliplatin 2Erlotinib Hydrochloride 2Early Intervention, Educational 2Carboplatin 2Biopsy 2toripalimab 1tipifarnib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Anus Neoplasms × VGX-3100 × Clear all
NCT03499795 2023-07-14

VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

Inovio Pharmaceuticals

Phase 2 Completed
23 enrolled 19 charts
GastrointestinalGynecologic

Squamous Intraepithelial Lesions, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡